ETR:MDG1 - MediGene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
€12.39 -0.30 (-2.36 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close€12.39
Today's Range€12.38 - €12.75
52-Week Range€8.53 - €19.27
Volume67,736 shs
Average Volume306,207 shs
Market Capitalization$392.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MediGene logoMedigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; EndoTAG-1 for the treatment of solid tumors; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and a research collaboration with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Martinsried, Germany.

Receive MDG1 News and Ratings via Email

Sign-up to receive the latest news and ratings for MDG1 and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange ETR
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolETR:MDG1
CUSIPN/A
Phone+49-89-2000330

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-142.41%
Return on Equity-14.40%
Return on Assets-11.01%

Miscellaneous

EmployeesN/A
Outstanding Shares22,120,000
Market Cap$392.27

MediGene (ETR:MDG1) Frequently Asked Questions

What is MediGene's stock symbol?

MediGene trades on the ETR under the ticker symbol "MDG1."

What price target have analysts set for MDG1?

4 Wall Street analysts have issued twelve-month price targets for MediGene's stock. Their forecasts range from €12.00 to €22.00. On average, they anticipate MediGene's share price to reach €16.13 in the next year. This suggests a possible upside of 30.1% from the stock's current price. View Analyst Ratings for MediGene.

What is the consensus analysts' recommendation for MediGene?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediGene in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of MediGene's key competitors?

Who are MediGene's key executives?

MediGene's management team includes the folowing people:
  • Prof. Horst Domdey, Co-Founder & Chairman of the Supervisory Board (Age 67)
  • Prof. Dolores J. Schendel, Chief Exec. Officer, Chief Scientific Officer & Member of Exec. Management Board
  • Prof. Ernst-Ludwig Winnacker, Co-Founder & Chairman Scientific Advisory Board (Age 77)
  • Mr. David Jakob Lemus MBA, CPA, COO, Member of Exec. Management Board and CEO of Medigene Inc (Age 55)
  • Dr. Thomas Taapken, Chief Financial Officer and Member of Exec. Management Board

Has MediGene been receiving favorable news coverage?

Media headlines about MDG1 stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MediGene earned a daily sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the company an impact score of 45.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

What is MediGene's stock price today?

One share of MDG1 stock can currently be purchased for approximately €12.39.

How big of a company is MediGene?

MediGene has a market capitalization of $392.27 million.

How can I contact MediGene?

MediGene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330.


MarketBeat Community Rating for MediGene (ETR MDG1)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about MediGene and other stocks. Vote "Outperform" if you believe MDG1 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDG1 will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.